Radu Ciubuc, MD
Geriatric Medicine · El Paso, TXNPI 1568477321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 46.1% of the total. Reporting peaked in 2024 at $631 and has fallen 73.4% since, to $167 in 2025.
Across 60 payments — averaging $27.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$757
- AbbVie$229
- Biogen$142
- Neurocrine Biosciences, Inc.$55
- GE HealthCare$46
- Alpha Cognition USA, Inc.$46
- plus $369 from 15 others
What the payments were for
- Food & beverage$1,644100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 9 | $757 |
| AbbVie(2 entities) | 19 | $229 |
| Biogen | 7 | $142 |
| Neurocrine Biosciences, Inc. | 2 | $55 |
| GE HealthCare | 2 | $46 |
| Alpha Cognition USA, Inc. | 1 | $46 |
| Eisai Inc. | 2 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Bayer | 1 | $28 |
| Tactile Systems Technology Inc | 2 | $28 |
| Kyowa Kirin, Inc. | 1 | $21 |
| AstraZeneca | 1 | $21 |
| C2n Diagnostics, LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$473
How this compares
$1,644 in reported general payments places this provider in the 85th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $111,086 |
| JanuviaSitagliptin Phosphate | 261 | $80,306 |
| EliquisApixaban | 202 | $73,507 |
| Invega SustennaPaliperidone Palmitate | 26 | $65,779 |
| NuedextaDextromethorphan Hbr/Quinidine | 67 | $46,904 |
| NamzaricMemantine Hcl/Donepezil Hcl | 123 | $46,648 |
| MyrbetriqMirabegron | 131 | $44,172 |
| XareltoRivaroxaban | 127 | $43,364 |
| XifaxanRifaximin | 21 | $31,502 |
| OzempicSemaglutide | 12 | $20,789 |
| GemtesaVibegron | 67 | $20,421 |
| Sevelamer Carbonate | 58 | $18,008 |
| Levothyroxine Sodium | 1,630 | $17,860 |
| LinzessLinaclotide | 37 | $17,736 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $14,982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $55 | $111,08617 claims |
| AbbVieNamzaric, Linzess | $229 | $64,384160 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $44,172131 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $19 | $31,50221 claims |
| Boehringer IngelheimCombivent Respimat, Jardiance | $17 | $29,91663 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $41 | $20,42167 claims |
| AstraZenecaFarxiga | $21 | $14,19926 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $11 | $6,54414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 275 geriatric medicine providers in Texas.
Other geriatric medicine in El Paso
- Humberto Saenz ChavezEl Paso$3K
- Mauricio Gonzalez-AriasAustin$825K
- Eberenne IgbokwePearland$124K
- Diana KerwinDallas$81K
- David SmithBrownwood$19K
- Alejandro ArizmendiHelotes$15K
- Rosa VizcarraSan Antonio$9K
- George TaffetHouston$9K
- John CarrollCorpus Christi$8K
- Santos SoberonBeaumont$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.